Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors

doi:10.12998/wjcc.v12.i13.2143

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (271)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

213

Sum=223

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=29

May 6, 2024 (publication date) through May 9, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Cases. May 6, 2024; 12(13): 2143-2146
Published online May 6, 2024. doi: 10.12998/wjcc.v12.i13.2143

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors

Mohamed Wishahi

Mohamed Wishahi, Department of Urology, Theodor Bilharz Research Institute, Cairo 12411, Egypt

Author contributions: Wishahi M conceived the design; analyzed published data; wrote, reviewed, and edited the manuscript; and revised and approved the final version.

Conflict-of-interest statement: The author confirms that he has no conflict of interest of any kind.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/

Corresponding author: Mohamed Wishahi, MD, PhD, Professor, Surgical Oncologist. Department of Urology, Theodor Bilharz Research Institute, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com

Received: December 18, 2023
Revised: February 10, 2024
Accepted: April 7, 2024
Published online: May 6, 2024

Core Tip

Core Tip: Neuroendocrine prostate cancer (NEPC) are aggressive metastatic tumors, and there are two distinct types. De novo NEPC, which is less than 2% of all prostate cancer, is categorized as an entity of the endocrine tumors. The other type is the treatment induced NEPC (t-NEPC) that develops in castration resistant prostate cancer (CRPC) following androgen deprivation therapy, and it is an aggressive metastatic tumor occurs in 10%-17% of patients with CRPC and metastatic cancer, with median survival of 7 months after diagnosis. Genomic, epigenetic, and transcriptional alternation has been reported to be involved in its development. Future expectations for treatment would be tumor-directed immunotherapy.